Beginning Jan. 1, 2012, Cook Medicals central venous catheters (CVCs) will be available to the members served by Novation, the supply contracting company for more than 30,000 members of VHA Inc., UHC, and Provista. This expands nationwide access to these devices through one of industrys leading healthcare supply contracting companies.
The contract includes access to Cooks comprehensive CVC product offering, including Spectrum® minocycline and rifampin impregnated catheters.
We are pleased that our relationship with Novation continues to grow as we add another business division to its distribution network, saya Dan Sirota, vice president and business unit leader of Cook Medicals Critical Care and Interventional Radiology divisions. Our Spectrum central venous catheter sets have been shown to minimize the risk of catheter-related bloodstream infections (CRBSIs). Cook is proud to partner with Novation in delivering a technology that helps prevent dangerous and potentially fatal infections and reduces healthcare costs to its expansive network of health care providers.
An estimated 78,000 patients are infected with CRBSIs in the U.S. annually with an average cost estimated at $16,550 to treat per infection. Two decades of evidence, including more than 21 peer-reviewed studies and meta-analyses, confirm that minocycline and rifampin catheters are the most effective tool available to prevent CRBSIs. In addition, Spectrum CVCs meet the newly released recommendations from the CDC for reducing CRBSI if maximal sterile barrier precautions havent helped a facility reach its goal.